Drug regulators in the United States this month will decide whether to approve the first ever sex drug for women with a so-called "disorder" of low desire.

Advisers to the powerful Food & Drug Administration will meet on June 18 on the outskirts of Washington DC to assess the merits of a drug called flibanserin, which has previously failed as an anti-depressant.